Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio > Development > Poziotinib

Poziotinib

Poziotinib

Exon 20 Insertion Mutations in EGFR and HER2 Constrict the TKI Binding Pocket

Poziotinib

Preclinical Studies Suggest Poziotinib Binds in the Active Site and Blocks ATP

Poziotinib

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Poziotinib is an investigational drug not yet approved by the FDA.

Poziotinib is a novel, orally available quinazoline-based tyrosine kinase inhibitor that irreversibly blocks signaling through the HER family of tyrosine-kinase receptors including HER1 (erbB1; EGFR), HER2 (erbB2), and HER4 (erbB4), as well as EGFR and HER2 mutations. This in turn can lead to blocking of downstream signaling and inhibition of the proliferation of tumor cells.

Development Indications

Non Small Cell Lung Cancer
  • POZ 202 (Phase 2): HER2 and EGFR Exon 20 Insertion Mutations Locally Advanced or Metastatic NSCLC
Breast Cancer
  • POZ 201 (Phase 2): HER2+ Metastatic Breast Cancer
  • POZ 101 (Phase 1b) Combination With T-DM1 in HER2+ Breast Cancer

Latest News on Poziotinib

  • Sep 5, 2018
    Spectrum Pharmaceuticals Announces Release of Poziotinib Abstract as Part of the IASLC 19th World Conference on Lung Cancer
    (Click Here for Press Release)
  • May 3, 2018
    Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center
    (Click Here for Press Release)
  • May 1, 2018
    Spectrum Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo Fisher Scientific
    (Click Here for Press Release)
  • Apr 23, 2018
    Publication of Poziotinib Data in Nature Medicine
    (Click Here for Press Release)
  • Apr 17, 2018
    Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers at the American Association for Cancer Research (AACR) in Chicago
    (Click Here for Press Release)
  • Apr 10, 2018
    Update of MD Andersonís Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients
    (Click Here for Press Release)
  • Oct 30, 2017
    Initiation of a Multicenter Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with Exon 20 Insertion Mutation in EGFR or HER2
    (Click Here for Press Release)
  • Oct 17, 2017
    Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 15-18, 2017
    (Click Here for Press Release)
  • Mar 30, 2017
    Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
    (Click Here for Press Release)
  • Dec 8, 2016
    Spectrum Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer
    (Click Here for Press Release)
  • Dec 5, 2016
    Abstracts on Poziotinib posted at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016
    (Click Here for Press Release)
For all Press Releases click here